X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

A Breakthrough Medication For Dystonia Is Being Developed

Content Team by Content Team
6th January 2023
in Drug Development, News

Thousands of musicians now have hope after substantial progress was made in the search for a dystonia cure by a research team in Korea.

1–3% of musicians worldwide suffer from musicians’ dystonia, while 5% of all dystonia sufferers are musicians. Dystonic musicians frequently struggle with mental health conditions, including stress and depression, since they are unable to rehearse and perform music owing to their condition. In extremely extraordinary situations, these have even prompted suicide.

It is known that due to their intense practise schedules, perfectionism, and genetic predispositions, musicians are especially vulnerable to illnesses like dystonia.

The World Health Organization (WHO) and well-known pianist Joo Carlos Martins, a dystonia patient, sponsored the Conference for Musicians with Dystonia, where scientists from the Korea Advanced Institute of Science and Technology (KAIST), led by Professor Daesoo Kim, recently presented findings on a novel treatment for the condition.

Due to focal dystonia in his fingers, Martins was forced to put an end to his career as a pianist. Martins was able to appear once more at Carnegie Hall on November 19, 2022, even though he was 82 years old. Ubirat Bizarro Costa, an industrial designer, created a bionic glove that Martins started using in 2020.

Dystonia therapies currently available

Currently, the condition’s aberrant muscular activities are suppressed with botulinum toxin (Botox). However, blocking muscular function will ultimately prevent musicians from playing their instruments. Martins underwent three brain surgeries and numerous Botox treatments, but neither therapy had a therapeutic effect. Researchers created novel therapeutic strategies as a result of this.

The study group led by Professor Kim discovered that too much stress results in aberrant muscular tension. The researchers created NT-1, a medication that stops the brain from developing signs of dystonia, allowing patients to use their muscles normally.

Although dystonia is not as well known, it is a common disease worldwide and requires society’s attention as well as the dedication of many researchers, according to the Director of the Mental Health and Substance Use Division at WHO, who made the statement during the WHO conference.

NT-1 is a medication that prevents the brain’s source of dystonia and enables musicians to continue practising their instruments. By 2024, they hope to have clinical approval in Korea, said Professor Kim.

Clinical tests for NT-1 are currently being conducted

Professor Kim is serving as CEO of NeuroTobe, a faculty-led start-up firm at KAIST that is currently developing the NT-1 therapy. The drug’s synthesis for clinical testing was successfully completed, and multiple iterations of animal testing revealed good efficacy and safety.

Contrary to Botox, which might take several days to exhibit its therapeutic benefits after obtaining the treatment from a hospital, NT-1 begins to work within an hour of taking it. NT-1, which has been compared to edible Botox, is anticipated to aid in the treatment of a number of muscle disorders and diseases.

Previous Post

Australia Introduces A New Tool To Lower Medicine Costs

Next Post

Sirio Pharma Successfully Completes the Acquisition of Best Formulations

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

Sirio Pharma Successfully Completes the Acquisition of Best Formulations

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In